Skip to main content
SpringerLink
Log in

Phase II trial of the novel sulphonylurea sulofenur in advanced breast cancer

  • Short Communication
  • Phase II, Sulphonylurea Sulofenur, Advanced Breast Cancer
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Summary

A total of 18 women with advanced breast cancer were treated with sulofenur [LY186641;N-(5-indanylsulfonyl)-N′-(4-chlorophenyl)-urea], a diarylsulfonylurea that has broad-spectrum activity against a number of murine mammary tumour xenografts. The dosage chosen on the basis of pre-clinical and phase I studies was 700 mg/m2 given orally once daily for 14 days, with treatments being repeated every 3 weeks. There was no response. All patients experienced at least grade 1 anaemia, and two patients developed symptomatic methaemoglobinaemia. Two patients developed grade 4 rises in serum liver-function values along with histological changes consistent with drug-induced toxicity. The mean plasma concentrations of 176 μg/ml were lower than the levels required to exert anti-tumour effect in the mouse model.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Armand JP, Recondo G, Gouyette A, Belerahdek M, Bonnay M, Chabot G, L'Homme C (1989) Phase I and pharmacokinetic study of LY186641 administered daily for 2 weeks every 21 days. Proceedings, 4th NCI EORTC Symposium on New Drugs in Cancer Chemotherapy, Amsterdam 1989, p 300

  2. Boder GB, Beasley FW, Grindey GB (1989) Mechanism of action studies with LY186641. Proc Am Assoc Cancer Res 30: 554

    Google Scholar 

  3. Cancer Registry (1990) Cancer statistics: registration 1985. Series MBI 18, England and Wales, 1985. HMSO, London

    Google Scholar 

  4. Ehlhardt WJ (1991) Metabolism and disposition of the anti-cancer agent sulofenur in mouse, rat, monkey and human. Drug Metab Dispos 19: 370

    Google Scholar 

  5. Ehlhardt WJ, Howbert JJ (1991) Metabolism and disposition ofp-chloroaniline in rat, mouse and monkey. Drug Metab Dispos 19: 366

    Google Scholar 

  6. Fraser BM, Steward WK (1977) Cholestatic jaundice following chlorpropramide self poisoning. Clin Toxicol 11: 13

    Google Scholar 

  7. Grindey GB (1988) Identification of diarylsulfonylureas as novel anticancer drugs. Proc Am Assoc Cancer Res 29: 535

    Google Scholar 

  8. Hainsworth JD, Hande KR, Satterlee WG, Kuttesch J, Johnson DH, Grindey G, Jackson LE, Greco FA (1989) Phase I clinical study ofN-[(4-chlorophenyl)-amino]carbonyl-2,3-dihydro-1H-indene-5-sulfonamide (LY186641). Cancer Res 49: 5217

    Google Scholar 

  9. Hande KR, Kuttesch J, Hamilton M, Satterlee W, Jackson L, Grindey G, Hainsworth JD (1990) Kinetics ofN-[(4-chlorophenyl)amino]carbonyl-2,3-dihydro-1H-indene-5-sulfonamide (LY186641) in humans. Cancer Res 50: 3910

    Google Scholar 

  10. Houghton PJ, Houghton JA, Myers L, Cheshire P, Howbert JJ, Grindey GB (1989) Evaluation ofN-(5-indanylsulfonyl)-N′-(4-chlorophenyl)-urea against xenografts of pediatric rhabdomyosarcoma. Cancer Chemother Pharmacol 25: 84

    Google Scholar 

  11. Houghton PJ, Bailey FC, Houghton JA, Murti KG, Howbert JJ, Grindey GB (1990) Evidence for mitochondrial localisation ofN-(4-methylphenylsulfonyl)-N′-(4-chlorophenyl)urea in human colon adenocarcinoma cells. Cancer Res 50: 664

    Google Scholar 

  12. Kamthan A, Scarffe JH, Walling J, Hatty S, Coleman R, Smyth JF (1992) A phase II study of sulofenur (LY186641) in gastric cancer. Anti Cancer Drugs 3: 331

    Google Scholar 

  13. Kiese M (1974) Methaemoglobinaemia: a comprehensive treatise. CRC Press, Cleveland, Ohio

    Google Scholar 

  14. Kuhn J, Craig J, Howlin K, Brown T, Beougher K, Van Hoff D, Satterlee W, Hamilton MJ (1988) Clinical phase I clinical and pharmacokinetic evaluation of oral LY186641 in a single 21 day schedule. Proc Am Soc Clin Oncol 7: 60

    Google Scholar 

  15. O'Brien MER, Hardy J, Tan S, Walling J, Peters B, Hatty S, Wiltshaw E (1992) A phase II study of sulofenur (a novel sulphonylurea LY186641) in recurrent epithelial ovarian cancer. Cancer Chemother Pharmacol 30: 245

    Google Scholar 

  16. Taylor CW, Alberts DS, Ketcham MA, Satterlee WG, Holdsworth MT, Plezia PM, Peng YM, McCloskey TM, Roe DJ, Hamilton M, Salmon SE (1989) Clinical pharmacology of a novel diarylsulfonylurea anticancer agent. J Clin Oncol 11: 1733

    Google Scholar 

  17. WHO (1979) Handbook for reporting results in cancer treatment. Offset publication 48. Geneva

Download references

Author information

Authors and Affiliations

  1. Breast Unit, Royal Marsden Hospital, SW3 6JJ, London, UK

    Denis C. Talbot, Ian E. Smith, Marianne C. Nicolson, Trevor J. Powles & Diane Button

  2. Sutton, UK

    Denis C. Talbot, Ian E. Smith, Marianne C. Nicolson, Trevor J. Powles & Diane Button

  3. Medical Department, Lilly Industries Limited, Dextra Court, RG21 2SY, Basingstoke, Hants, UK

    Jackie Walling

Authors
  1. Denis C. Talbot
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ian E. Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Marianne C. Nicolson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Trevor J. Powles
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Diane Button
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jackie Walling
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Talbot, D.C., Smith, I.E., Nicolson, M.C. et al. Phase II trial of the novel sulphonylurea sulofenur in advanced breast cancer. Cancer Chemother. Pharmacol. 31, 419–422 (1993). https://doi.org/10.1007/BF00686159

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00686159

Keywords

Search

Navigation